GLP1R and type 2 diabetes mellitus: In 2019, dulaglutide was approved by the National Medical Products Administration (NMPA) for glycemic control by means of monotherapy plus diet and exercise or as an add‐on to other non‐GLP‐1 agents in the T2DM population [7].